Volume 1, Issue 11
News and Viewsp. 1475
Investigational drug shows significant improvement in cancer survival rate
Interviewp. 1479
Why are epilepsy trials failing? Interview with Emilio Perucca
Author(s): Emilio Perucca
Interviewp. 1487
Why are epilepsy trials failing? Interview with Russell Katz
Author(s): Russell Katz
Review Articlep. 1491
Current conceptions of the etiology and risk factors for Alzheimer\\\'s disease and their possible implications on the design of dementia clinical trials
Author(s): Ramit Ravona-Springer, Amos D Korczyn
Review Articlep. 1505
New considerations in the design of clinical trials for spondyloarthritis
Author(s): Robert Landewe ,Desiree van der Heijde
Therapeutic Prospectivep. 1513
Pharmacogenomic testing to guide treatment using antipsychotic medications
Author(s): David A Mrazek
Therapeutic Prospectivep. 1523
Early vascular aging syndrome: background and proposed definitions
Author(s): Peter Nilsson
Review Articlep. 1533
The unfolding treatment landscape for men with astration-resistant prostate cancer
Author(s): Jenny J Kim, Daniel Keizman, Samuel R Denmeade,Emmanuel S Antonarakis
Review Articlep. 1545
Poly(ADP-ribose) polymerase inhibitors in breast cancer and other tumors: advances and challenges
Author(s): Mustafa Khasraw, Mark Robson
Review Articlep. 1555
Clinical evidence of the role of belimumab in the treatment of systemic lupus erythematosus
Author(s): Ricard Cervera, Gerard Espinosa
Review Articlep. 1563
New and emerging therapies for gout
Author(s): Daria B Crittenden, Han Na Kim, Mark C Fisher, David S Goldfarb, Michael H Pillinger
Review Articlep. 1577
New-generation triazole antifungal drugs: review of the Phase II and III trials
Author(s): Corrado Girmenia,Erica Finolezzi
